Search results for "GANCICLOVIR"

showing 10 items of 28 documents

Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and arte…

2018

Hybridization of natural products has high potential to further improve their activities and may produce synergistic effects between linked pharmacophores. Here we report synthesis of nine new hybrids of natural products egonol, homoegonol, thymoquinone and artemisinin and evaluation of their activities against P. falciparum 3D7 parasites, human cytomegalovirus, sensitive and multidrug-resistant human leukemia cells. Most of the new hybrids exceed their parent compounds in antimalarial, antiviral and antileukemia activities and in some cases show higher in vitro efficacy than clinically used reference drugs chloroquine, ganciclovir and doxorubicin. Combined, our findings stress the high pot…

0301 basic medicineGanciclovirCell SurvivalPlasmodium falciparumClinical BiochemistryMolecular ConformationCytomegalovirusPharmaceutical ScienceAntineoplastic AgentsAnisolesPharmacologyCrystallography X-RayAntiviral Agents01 natural sciencesBiochemistryAntimalarials03 medical and health scienceschemistry.chemical_compoundChloroquineCell Line TumorDrug DiscoveryBenzoquinonesmedicineAnimalsHumansPotencyDoxorubicinAntimalarial AgentArtemisininMolecular BiologyThymoquinoneBenzofuransBiological Products010405 organic chemistryChemistryOrganic ChemistryArtemisinins0104 chemical sciences030104 developmental biologyMolecular MedicinePharmacophoremedicine.drugBioorganic & Medicinal Chemistry
researchProduct

2017

Many quinazoline derivatives have been synthesized over the last few decades with great pharmacological potential, such as antimalarial, anti-inflammatory, antimicrobial, anticancer, and antiviral. But so far, no quinazoline–artemisinin hybrids have been reported in the literature. In the present study, five novel quinazoline–artemisinin hybrids were synthesized and evaluated for their in vitro biological activity against malarial parasites (Plasmodium falciparum 3D7), leukemia cells (CCRF-CEM and CEM/ADR5000), and human cytomegalovirus. Remarkably, hybrid 9 (EC50 = 1.4 nM), the most active antimalarial compound of this study, was not only more potent than artesunic acid (EC50 = 9.7 nM) but…

0301 basic medicineGanciclovirGeneral Chemical Engineeringmedicine.medical_treatmentDihydroartemisininPharmacology01 natural sciences03 medical and health scienceschemistry.chemical_compoundChloroquineparasitic diseasesmedicineQuinazolineArtemisininbiology010405 organic chemistryPlasmodium falciparumBiological activityGeneral ChemistryAntimicrobialbiology.organism_classificationVirology0104 chemical sciences030104 developmental biologychemistrymedicine.drugACS Omega
researchProduct

Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNγ CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia an…

2009

Rising levels of cytomegalovirus (CMV) DNAemia and/or pp65 antigenemia have been observed during pre-emptive ganciclovir therapy in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT). We assessed the incidence of this event in our series, and investigated whether its occurrence was associated with an impairment in the CMV-specific T-cell response. A total of 36 allo-SCT recipients experienced one or more episodes of active CMV infection (n=68) that were pre-emptively treated with val(ganciclovir). Rising levels of antigenemia and DNAemia, and an isolated increase in antigenemia, were observed in 39.7 and 2.9% of all episodes, respectively. Receipt of corticost…

AdultCD4-Positive T-LymphocytesMaleGanciclovirAdolescentvirusesCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesOpportunistic Infectionsmedicine.disease_causeHerpesviridaeImmediate-Early ProteinsViral Matrix ProteinsInterferon-gammaYoung AdultAntigenBetaherpesvirinaeDrug Resistance ViralmedicineHumansTransplantation HomologousAntigens ViralGanciclovirAgedTransplantationbiologybusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesHematologyMiddle AgedPhosphoproteinsbiology.organism_classificationmedicine.diseaseTransplantationsurgical procedures operativeCytomegalovirus InfectionsDNA ViralMutationImmunologyFemaleStem cellbusinessCD8medicine.drugBone Marrow Transplantation
researchProduct

Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood

2015

Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood

AdultMale0301 basic medicineAdolescent030106 microbiologyCytomegalovirusVirus ReplicationAntiviral AgentsYoung Adult03 medical and health sciences0302 clinical medicineHumansTransplantation HomologousMedicineDoubling timeProgenitor cellGanciclovirAgedTransplantationbusiness.industryHematopoietic Stem Cell TransplantationAntiviral therapyHematologyMiddle Agedmedicine.diseaseTransplantationGraft-versus-host diseaseCytomegalovirus InfectionsDNA ViralImmunologyFemaleStem cellbusiness030215 immunologyBone Marrow Transplantation
researchProduct

Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8 + T Cells To Predict CMV DNAemia Clearance in …

2014

ABSTRACT It is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting cytomegalovirus (CMV) DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. In this observational study, including 13 episodes of CMV DNAemia treated with intravenous (i.v.) GCV or oral valganciclovir, we showed that monitoring trough plasma GCV levels does not reliably predict response to therapy. Rather, immunological monitoring (pp65 and immediate-early [IE]-1-specific gamma interferon [IFN-γ]-producing CD8 + T cells) appeared to perform better for this purpose.

AdultMaleGanciclovirvirusesCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesClinical TherapeuticsViral Matrix ProteinsInterferon-gammamedicineHumansValganciclovirCytotoxic T cellPharmacology (medical)GanciclovirMultiple myelomaPharmacologybusiness.industryLymphoma Non-HodgkinAnemia Aplasticvirus diseasesValganciclovirMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaPhosphoproteinsmedicine.diseaseTransplant RecipientsLeukemia Myeloid AcuteLeukemiaInfectious DiseasesCytomegalovirus InfectionsDNA ViralImmunologyFemaleStem cellMultiple MyelomabusinessCD8Stem Cell Transplantationmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.

2015

Background This study aimed to characterize the dynamics of acquisition of cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) in CMV donor positive/recipient negative solid organ transplant (SOT) patients receiving long-term antiviral prophylaxis, and to determine whether development of CMI confers protection against CMV disease. Methods A prospective multicenter study was conducted in Spain from September 2009 to September 2012. Whole blood specimens were prospectively collected at 30, 90, 120, 200, and 365 days after SOT, and CMI was determined by enumeration of CMV pp65 and IE-1-specific CD69+/interferon-γ-producing CD8+ and CD4+ T cells by flow cytometry for intracellular cytok…

AdultMalemedicine.medical_specialtyCongenital cytomegalovirus infectionCytomegalovirusDiseaseKaplan-Meier EstimateGastroenterologyAntiviral AgentsPostoperative ComplicationsImmunityInternal medicinemedicineHumansValganciclovirProspective StudiesGanciclovirSurvival analysisAgedPostoperative CareTransplantationImmunity Cellularbusiness.industryIncidence (epidemiology)Organ TransplantationMiddle Agedmedicine.diseaseTransplantationClinical trialInfectious DiseasesTreatment OutcomeImmunologyCytomegalovirus InfectionsFemalebusinessCD8Follow-Up StudiesTransplant infectious disease : an official journal of the Transplantation Society
researchProduct

Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice

2015

Producción Científica

AdultMalemedicine.medical_specialtyRiñones - TrasplanteCongenital cytomegalovirus infectionCytomegaloviruskidney transplantationSIDA (Enfermedad)Kaplan-Meier EstimateDiseaseAntiviral AgentsAsymptomaticRisk FactorsInternal medicineseropositive recipientpreemptive therapymedicineHumansValganciclovirProspective StudiesRenal InsufficiencyPropensity ScoreGanciclovircytomegalovirusKidney transplantationAgedProportional Hazards ModelsTransplantation3205.06 Nefrologíabusiness.industryProportional hazards modelIncidenceIncidence (epidemiology)antiviral prophylaxisMiddle Agedmedicine.diseaseKidney TransplantationDiscontinuationSurgerymulticenter studySpainCytomegalovirus InfectionsPropensity score matchingFemalemedicine.symptombusinessImmunosuppressive AgentsGlomerular Filtration Rate
researchProduct

Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation.

2002

Although ganciclovir (GCV) is most often used in suicide anticancer gene therapy, the mechanism of GCV-induced cell killing and apoptosis is not fully understood. We analysed the mechanism of apoptosis triggered by GCV using a model system of CHO cells stably transfected with HSV-1 thymidine kinase (HSVtk). GCV-induced apoptosis is due to incorporation of the drug into DNA resulting in replication-dependent formation of DNA double-strand breaks and, at later stages, S and G2/M arrest. GCV-provoked DNA instability was likely to be responsible for the observed initial decline in Bcl-2 level and caspase-9/-3 activation. Further decline in the Bcl-2 level was due to cleavage of the protein by c…

Cancer ResearchTime FactorsvirusesPoly ADP ribose polymeraseApoptosisCytochrome c GroupCHO CellsHerpesvirus 1 HumanTransfectionThymidine KinaseCricetinaeGeneticsAnimalsfas ReceptorMolecular BiologyGanciclovirbiologyReverse Transcriptase Polymerase Chain ReactionCytochrome cCell CycleTransfectionSuicide geneFas receptorMolecular biologyCaspase 9Enzyme ActivationGene Expression Regulation NeoplasticCell killingProto-Oncogene Proteins c-bcl-2ApoptosisThymidine kinaseCaspasesbiology.proteinPoly(ADP-ribose) PolymerasesDNA DamageOncogene
researchProduct

Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell tran…

2010

The dynamics of CMV pp65 and IE-1-specific IFNgamma-producing CD8(+) (IFNgamma CD8(+)) and CD4(+) (IFNgamma CD4(+)) T cells and CMV DNAemia were assessed in 19 pre-emptively treated episodes of active CMV infection. Peripheral counts of IFNgamma CD8(+) and IFNgamma CD4(+) T cells inversely correlated with CMV DNAemia levels (P = <0.001 and P = 0.003, respectively). A threshold value of 1.3 cells/microl predicting CMV DNAemia clearance was established for IFNgamma CD8(+) T cells (PPV, 100%; NPV, 93%) and for IFNgamma CD4(+) T cells (PPV, 100%; NPV, 75%). Undetectable T-cell responses were usually observed at the time of initiation of pre-emptive therapy. Either a rapid (within 7 days) or a d…

GanciclovirAdultCD4-Positive T-LymphocytesMaleAdolescentEndpoint DeterminationCongenital cytomegalovirus infectionCytomegalovirusT-Cell Antigen Receptor SpecificityBiologyCD8-Positive T-LymphocytesImmediate early proteinImmediate-Early ProteinsViral Matrix ProteinsInterferon-gammaImmune systemVirologymedicineHumansTransplantation HomologousInterferon gammaLymphocyte CountAgedvirus diseasesMiddle Agedmedicine.diseasePhosphoproteinsVirologyTransplantationInfectious DiseasesImmunologyCytomegalovirus InfectionsDNA ViralFemaleViral loadCD8medicine.drugStem Cell TransplantationJournal of medical virology
researchProduct

A QSAR study investigating the potential anti-HIV-1 effect of some acyclovir and ganciclovir analogs

2009

A QSAR study, involving the use of calculated physical-chemical properties (TSAR TM ), and the use of a neural network approach (TSAR TM ), has been performed on the potential anti-HIV-1 activity of a series of Acyclovir and Ganciclovir analogs. Model obtained allows reliable predictions for the anti-HIV-1 activity of these derivatives, and showed that the presence of the Ganciclovir chain in triazolopyrrolopyrimidine and pyrimidopyrrolopyrimidine series seems to increase the antiviral effect.

GanciclovirAnti hiv 1Quantitative structure–activity relationshipStereochemistryChemistryOrganic ChemistrymedicineQSAR neural network BMLR anti-HIV-1 activityvirus diseasesPharmacologySettore CHIM/08 - Chimica Farmaceuticamedicine.drug
researchProduct